Darbepoetin alfa in lung cancer patients on chemotherapy: a retrospective comparison of outcomes in patients with mild versus moderate-to-severe anaemia at baseline

摘要: Currently, there is some debate concerning the haemoglobin level at which treatment of anaemia with erythropoiesis-stimulating agents should be initiated in cancer patients on chemotherapy. We report several analyses data from a phase III trial darbepoetin alfa versus placebo, comparing outcomes for mild and moderate-to-severe anaemia. Data were obtained placebo anaemic lung receiving chemotherapy (n=314). Outcomes compared baseline ≥10–11 g/dl <10 g/dl. Darbepoetin significantly reduced transfusions irrespective initiation. For <10 g/dl, 31% 59% those respectively, required transfusion week 5 to end (P<0.038). ≥10 g/dl, proportions 15% 41%, respectively (P<0.001). also improved fatigue both categories. These findings show that initiating levels <10 g/dl results substantial clinical benefits, supporting use erythropoietic therapy